Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 58-66

  Vredenburgh, James J ^a   Desjardins, Annick ^a   Kirkpatrick, John P ^a   Reardon, David A ^a   Peters, Katherine B ^a   Herndon II, James E ^a   Marcello, Jennifer ^a   Bailey, Leighann ^a   Threatt, Stevie ^a   Sampson, John ^a   Friedman, Allan ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Glioblastoma multiforme; Radiation therapy; Temozolomide

Indexed keywords

BEVACIZUMAB; CENTRAL NERVOUS SYSTEMS; CLINICAL TARGET VOLUMES; GLIOBLASTOMA MULTIFORME; IRINOTECAN; NEWLY DIAGNOSED GLIOBLASTOMA; PERFORMANCE STATUS; PROGRESSIVE DISEASE; PULMONARY EMBOLUS; SURGICAL INTERVENTIONS; TEMOZOLOMIDE; TOTAL DOSE;

RADIATION; RADIOTHERAPY; STANDARDS; TOXICITY;

DISEASE CONTROL;

ANTICONVULSIVE AGENT; BEVACIZUMAB; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; IRINOTECAN; PENTAMIDINE; TEMOZOLOMIDE;

ABSCESS; ADD ON THERAPY; ADULT; AGED; ANUS FISSURE; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLON PERFORATION; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; CRANIOTOMY; DEBRIDEMENT; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FAILURE TO THRIVE; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTUM ABSCESS; SEIZURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; WOUND ABSCESS; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHEMORADIOTHERAPY; CRANIOTOMY; DACARBAZINE; DEXAMETHASONE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TUMOR BURDEN; YOUNG ADULT;

EID: 83955165997     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.08.058     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts & Figures 2009. Factors that influence cancer rates. Atlanta, GA: American Cancer Society. p. 68.
2. S.A. Grossman, X. Ye, and M. Chamberlain Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial J Clin Oncol 27 2009 4155 4161
3. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
4. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
5. K. Lamszus, U. Ulbricht, and J. Matschke Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A Clin Cancer Res 9 2003 1399 1405
6. A. Salmaggi, M. Eoli, and S. Frigerio Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma J Neurooncol 62 2003 297 303
7. P. Birner, M. Piribauer, and I. Fischer Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes Brain Pathol 13 2003 133 143
8. M.A. Cobleigh, V.K. Langmuir, and G.W. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 2003 117 124
9. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
10. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
11. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
12. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
13. D.R. MacDonald, T.L. Cascino, and S.C. Schold Jr. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
14. S.M. Chang, J. Clark, and P.Y. Wen Novel imaging response assessment for drug therapies in recurrent malignant glioma ASCO Educational Book 2009 107 111 American Society of Clinical Oncology, Alexandria, Virginia.
15. S. Godard, G. Getz, and M. Delorenzi Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes Cancer Res 63 2003 6613 6625
16. G.L. Semenza Intratumoral hypoxia, radiation resistance, and HIF-1 Cancer Cell 5 2004 405 406
17. P.R. Wachsberger, R. Burd, and C. Cardi VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma Int J Radiat Oncol Biol Phys 67 2007 1526 1537
18. G.R. Criscuolo The genesis of peritumoral vasogenic brain edema and tumor cysts: A hypothetical role for tumor-derived vascular permeability factor Yale J Biol Med 66 1993 277 314
19. E.R. Gerstner, D.G. Duda, and E. di Tomaso VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer Nat Rev Clin Oncol 6 2009 229 236
20. D. Brandsma, L. Stalpers, and W. Taal Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 2008 453 461
21. G.A. Alexiou, S. Tsiouris, and A.P. Kyritsis Glioma recurrence versus radiation necrosis: Accuracy of current imaging modalities J Neurooncol 95 2009 1 11
22. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
23. L.C. Marras, W.H. Geerts, and J.R. Perry The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review Cancer 89 2000 640 646
24. S. Iodice, S. Gandini, and M. Lohr Venous thromboembolic events and organ-specific occult cancers: A review and meta-analysis J Thromb Haemost 6 2008 781 788
25. E. Pan, J.S. Tsai, and S.B. Mitchell Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients Anticancer Res 29 2009 4309 4313
26. S.E. Combs, J. Wagner, and M. Bischof Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients Int J Radiat Oncol Biol Phys 70 2008 987 992
27. H.J. Jeon, D.S. Kong, and K.B. Park Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: Single-center experience Clin Neurol Neurosurg 111 2009 679 682
28. A. Lai, E. Filka, and B. McGibbon Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 2008 1372 1380